Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Contact surface area predicts renal function in patients after partial nephrectomy

01 Mar 2018

There exists an association between contact surface area (CSA) and the change in postoperative renal function after partial nephrectomy, a recent study has found. CSA can be used together with the nephrometry score to advise patients regarding the risk of renal functional decline after partial nephrectomy.

A total of 257 partial nephrectomy patients were included in the analysis. Median CSA was 14.5 cm2 (interquartile range [IQR], 6.2–36) and the median nephrometry score was 9 (IQR, 7–10).

In Spearman correlation analysis, CSA was associated with estimated blood loss (rs, 0.42; p<0.001), length of stay (rs, 0.18; p=0.005), and percent and absolute change in the estimated glomerular filtration rate (rs, –0.77 and –0.78; p<0.001).

Multivariable analysis revealed that CSA and nephrometry score independently predicted the absolute change in the estimated glomerular filtration rate (p<0.001). Furthermore, receiver operating characteristic curve analysis showed that CSA was better than the nephrometry score (AUC, 0.94 vs 0.80) in predicting >20-percent postoperative decline in the estimated glomerular filtration rate.

In this study, the investigators accessed a prospectively maintained kidney cancer database for patients treated with partial nephrectomy between 2014 and 2016. Data sourced from preoperative cross-sectional imaging were used to calculate CSA. The association between CSA and perioperative variables was then assessed.

In addition, the investigators examined the correlation between postoperative renal functional outcomes, CSA and the RENAL (radius, exophytic/endophytic properties, nearness of tumour to collecting system or sinus, anterior/posterior, location relative to polar lines, and tumour touches main renal artery or vein) nephrometry score.

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.